The pressing questions in multiple sclerosis Care in the era of COVID-19

• MS patients should continue their disease modifying therapy during the pandemic. • Newly diagnosed patients should start disease modifying therapy without delay. • The effect on COVID-19 infection and future vaccination should be considered. • Agents that cause prolonged non-selective lymphopenia...

Descripción completa

Detalles Bibliográficos
Autores principales: Abboud, Hesham, Serra, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308765/
https://www.ncbi.nlm.nih.gov/pubmed/32599294
http://dx.doi.org/10.1016/j.jns.2020.117005
Descripción
Sumario:• MS patients should continue their disease modifying therapy during the pandemic. • Newly diagnosed patients should start disease modifying therapy without delay. • The effect on COVID-19 infection and future vaccination should be considered. • Agents that cause prolonged non-selective lymphopenia are not preferred. • Only severe relapses should be treated preferably with oral steroids at home.

Ejemplares similares